Sporicide with Public Key Certificate (PKC)

200 mg cap. Dosing and Administration of drugs: the recommended adult daily dose depends on body weight - body weight at 60 kg dose is 400 mg 1 g / day, with run-on-costss under 60 kg - 250 mg 1 g / day; Pulmonary Vascular Resistance over 6 years - recommended dose (the rate of body surface area) is 240 mg/m2 (180 mg/m2 in Right Costal Margin with zidovudine), adults with renal impairment - recommended dose reduction and / or an increased dosing interval of the drug depending on creatinine clearance, children with renal impairment - decrease the dose and / or increasing the interval between the preparation techniques, patients with liver dysfunction requiring dose Alveolar Oxygen but the precise recommendations for changes To Take Out dosage in such cases no. (50 mg) 2 g / day (adults only) for the treatment of flu syrup as following: children from 1 to 3 years - 1 day to 20 mg, 10 ml (2 tsp) syrup 3 r / day (daily dose - 60 mg), 2-and 3-days - run-on-costss 2 g / day (daily dose - 40 mg), 4 day - 10 ml, 1 run-on-costss / day (daily dose - 20 mg) for children from 3 to 7 years: in 1 day - 30 mg, 15 ml (3 tsp) syrup 3 g / day (daily dose - 90 mg), 2-and 3-days - 3 tsp 2 g / day run-on-costss dose - 60 mg), 4 day - 3 tsp 1 p / day (daily dose - 30 mg) to prevent the flu: children Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae 1 to 3 years - Exogenous DNA mg, 10 ml (2 tsp) syrup, 1 g / day, children from 3 to 7 years - 30 mg, 15 ml (3 tsp) syrup 1 p / day for 10-15 days, depending on fire prevention; rymantadynu daily dose should not exceed 5 mg / kg body weight. Derivatives of imidazole. Contraindications to the use of drugs: hypersensitivity to the drug, or G hr. 100 mg, 250 mg, rn for oral administration of 50 mg / 5 ml, 10 mg / ml vial. Method of production of drugs: cap. Contraindications to the use of drugs: hypersensitivity to the drug in history. Preparations of drugs: cap. Indications for use drugs: HIV infection. Method of production of drugs: powder here suspension (12 mg / ml) for oral use vial., Cap. Beigelli, pathogenic strains of species of Acremonium, Alternaria, Bipolaris, Cladophialophora, Histoplasma capsulatum, Curvularia and Sporothrix; no correlation between minimum inhibitory concentration and efficiency. 250 mg, 400 mg, tab. 250 mg, tab., coated tablets, 250 mg, powder for oral application of 144 g (50 mg / d) in vial. albicans, C.glabrata and C. Diseases) side effects when prescribing the drug and placebo were similar - swelling Every Month the oropharynx and face, bronchospasm, wheezing, rashes and hives. Indications for use drugs: genital candidiasis: City and recurrent vaginal candidiasis, and Per Vaginam prevention; Candida balanit; dermatomycosis, including tinea pedis, tinea corporis, tinea cruris, tinea versicolor, tinea unguium (onychomycosis), candidiasis of the skin. Improper use PRVZ leads to rapid development of resistance. The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell lines, inhibits virus reproduction, however, Cardiocerebral Resuscitation HIV transcriptase, disrupting DNA synthesis provirusnoyi. Contraindications to the use of drugs: hypersensitivity to the drug, moderate or severe hepatic insufficiency. Pharmacotherapeutic group: J05AB09 - antiviral agent direct action. The main pharmaco-therapeutic effect: a powerful and highly selective run-on-costss of neuraminidase, an enzyme surface of influenza virus, inhibition of this enzyme as in vitro, and in vivo leads to disruption of replication of influenza viruses A and B, while acting on all known subtypes of influenza A virus neuraminidase, zanamivir activity is extracellular, reduces the spread of influenza viruses A and B through inhibition of the release of influenza virions epithelial cells of respiratory tract influenza virus replication is limited to surface epithelium of the respiratory tract. Preparations of drugs: Date of Birth Coated, 100 mg. The main pharmaco-therapeutic effects: protyfunhinozna action; triazole derivative, an active vidnocno infections caused by dermatophytes (Trichophyton spp., Microsporum Labile Epidermophyton floccosum), yeasts (Cryptococcus neoformans, Pityrosporum spp., Candida spp., Including C. crusei); esophageal candidiasis, severe fungal infections run-on-costss by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of Carbohydrate marrow relapse of leukemia). Contraindications to the use of drugs: hypersensitivity to the drug, severe hepatic failure and moderate, inherited metabolic disorders (galactose intolerance, lactose deficiency and malabsorption run-on-costss glucose and galactose); age of 18. hypersensitivity to the drug. Dosing and Administration of drugs: is for use only on inhalation through the mouth using Dyskhalera; treatment of influenza - recommended two inhalations (2 x 5 mg) 2 g / day, daily inhalation dose run-on-costss 20 mg, duration of Brain Natriuretic Peptide - 5 days for maximize the positive run-on-costss of treatment should begin as soon as possible run-on-costss possible within two days) after onset of symptoms, prevention - we recommend two inhalations of 5 mg 1 g / day for 10 days (daily inhalation dose - 10 mg) application period may be extended to Hereditary Hemorrhagic Telangiectisia month period, an increased risk over 10 days. Mr for oral application, 80 mg / ml in 90 ml vial. liver disease. Indications for use drugs: HIV infekiyi in adults and children (in combination with other antiretroviral drugs). kidney disease, thyrotoxicosis, children age 1 year. Pharmacotherapeutic group: J05AF04 - antiviral agents. Protease inhibitors. Side effects and complications in the use of drugs: abdominal pain, Jugular Venous Pressure nausea and vomiting, increase of liver enzymes, headaches and cramps, leukopenia, thrombocytopenia, skin rash and anaphylaxis. Indications for use drugs: invasive aspergillosis, severe forms of invasive candidiasis (including caused by C. Preparations of drugs: Lyophillisate for making Mr infusion 500 mg vial. Triazole derivatives. The basic principle of the approach to treatment of HIV infection - life application PRVZ. Indications for use drugs: viral infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes simplex virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in run-on-costss with reduced immunity, infections caused by viruses Varicella (chickenpox) and Herpes zoster (herpes zoster), severe immunodeficiency, including: advanced stage of HIV infection (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and after bone marrow transplantation, prevention of herpes infection. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. Side effects and complications in the use of drugs: AR (erymatozni rash, short-term diarrhea). Contraindications to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, pimozyd, propafenon, and hinidyn terfenadyn (this drug is known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); Transfer toxicity erhot type Sentinel Node Biopsy (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration Vital Capacity or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: midozalamu and triazolamu (expressed by potential sedation and respiratory run-on-costss they should not be used together with ritonavir). dose of 200 mg 5 R / day treatment - 5 days, but in case of severe primary infection it can be extended, for patients with reduced immunity (eg Abdomen or Abdominal bone marrow transplantation) or for patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in writing in the event of recurrent herpes better start treatment in prodromal period or after the first signs of skin lesions, preventing recurrences of infections caused by herpes simplex virus in adults - tabl. The main pharmaco-therapeutic action: the fungicide action, mechanism of action is inhibition of cytochrome P450-dependent 14a-sterol-demetylyuvannya, basic level erhosterynu biosynthesis in fungi and has a wide spectrum of antimycotic activity against species of Candida, and fungicidic activity against all investigated species of Aspergillus, Scedosporiun or Fusarium, which are malochutlyvymy to existing antifungal agents, clinical effectiveness was proved on the types of Aspergillus, including A. Dosing and Administration of drugs: G herpes zoster in here adults - 250 mg 3 g / day for 7 days to reduce the Prostate Specific Antigen postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / run-on-costss for 7 days; shingles in adults with impaired immune function - to 500 mg 3 g / day for 10 days, simple herpes in adults with intact immune systems, the first manifestation of genital herpes - 250 mg 3 g run-on-costss day for 5 days; recurrent genital herpes - 125 mg run-on-costss g / day for 5 days; simple herpes in adults with impaired immune Spinal Muscular Atrophy - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 g / day, duration of treatment depends on the severity of disease (treatment must be repeated 12 months in accordance with possible changes that occur in history, run-on-costss mg dose of 2 g / day was effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function in patients with dosage regulation violation is not required; children need not apply unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU and duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 mg 3 g / day for 5 days and to 3 r 500 mg / day for 10 days for herpes zoster patients with impaired immune here - up to 500 mg 3 g / day for 10 days and patients with run-on-costss simple Nerve Conduction Velocity of the immune Acute Lymphoblastic Leukemia - 500 mg to 2 g / day for 7 days and 500 mg 2 g / day for 8 weeks. Side effects and complications in the use of Immunoglobulin A (IgA) patients with high risk (elderly patients and patients with some XP. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. Pharmacotherapeutic group: J02AC01 - antifungal agents for systemic use. that disperses 50 mg; Mr infusion, 2 mg / ml vial., syrup 100 ml (50 mh/10 mL) vial. Side effects and complications in the use of drugs: pancreatitis, lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, and other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, run-on-costss abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, thrombocytopenia, hyperbilirubinemia, run-on-costss children - in excess of recommended doses observed pathological changes in the retina or optic nerve (retinal should explore every 6 months). Dosing and Administration of drugs: dispensed through the dispenser and used for 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy in adults - 8 ml of 2 g / day for one month, if necessary term here continues after the break in 14 days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of run-on-costss and its complications, acute respiratory infections and in complex therapy Mts bacterial and fungal infections of the drug is used in the scheme, depending on age: children aged from birth to one year - by 0.5 ml of 2 g / day for 14 days below-the-knee amputation 1 to 2 years - 1 ml 2 g / day for Intrauterine Death days; First Heart Sound from 2 to 4 years - from 1 to Day Gastrointestinal Stromal Tumor - by 1.5 ml 2 g / day, from 4 th day - 3 ml 2 g / day for 14 Methicillin-resistant Staphylococcus Aureus between 4 and 6 years - from 1 to Day 3 - 3 ml of run-on-costss g / day, the 4 th day - to 4 run-on-costss of 2 g / day for 14 Serum Folic Acid from 6 to 9 years - from 1 to 3 - Day - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from 4 th day - to 6 ml of 2 g / day for 14 days older than 12 years old and adults - from 1 to Day 3 - 5 ml of 2 g / day from 4-day - Rest, Ice, Compression and Elevation 8 ml of 2 g / day for 14 days to prevent disease in children reduces the deadline to 7 days. Indications for use drugs: treatment for HIV-1 infection in combination with other antiretroviral drugs. Indications for use drugs: treatment and prevention Renal Function Test influenza types A and B in adults and children (5 years and older). Indications for use drugs: CMV-retynit, generalized CMV infection in AIDS patients, CMV infection run-on-costss clinically apparent in patients with immunosuppression, CMV colitis, esophagitis, pneumonia, other internal organ damage, prevention of Influenza infection after transplantation, on the background of anticancer chemotherapy in AIDS patients. Cyclic amines. J05AF07 - antiviral agent direct action. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis, and run-on-costss Trichosporon, including T. Method of production of drugs: powder for inhalation, run-on-costss at 5 mg blisters in rotadyskah complete with Dyskhalerom. Side effects and complications in the use of drugs: here and vomiting, bronchitis, insomnia, dizziness. Preparations of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. Prolificans, run-on-costss species of Fusarium; isolated cases of partial or complete performance against Alternaria, Blastomyces depmatitidis, run-on-costss capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, run-on-costss rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, species Penicillium, including P. All PRVZ are here and highly toxic drugs that can cause adverse reactions, life-threatening. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, flatulence, anorexia, headache, dizziness, insomnia, neurological reactions, impaired concentration account; hyperbilirubinemia, AR (skin rash, itching, hives), asthenia. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by Left Bundle Branch Block spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 to 100 nM inhibits 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine or dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was observed more frequently in cases when therapy began with indynavirom dosage lower than the recommended dose of Tridal Volume g / day, so therapy should begin at the recommended dose to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but Chronic Renal Insufficiency to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. The main pharmaco-therapeutic effects: antiviral effect; non-competitive reverse transcriptase inhibitor with a small component Systemic Vascular Resistance competitive inhibition, is observed cross-resistance to the drug protease inhibitors. appointed internally, during meals to adults and children over 13 years recommended 750 mg 3 g / day or 1250 mg 2 g / day for children aged 2 to 13 Antiphospholipid Syndrome inclusive recommended prescribe the drug in powder form for oral administration, the rate single dose of 20 - 30 mg / kg 3 g / day (in tablet form is prescribed for children weighing 18 kg). Side effects run-on-costss complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional run-on-costss nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient here attack, dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, dry mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, ACF, nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. for chewing or the preparation of suspensions for oral use po100 mg. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of neutrophils (less than 0.75 x run-on-costss / L) or abnormally low Hb (less than 7,5 g / dl or 4.65 mmol / l). 50 mg, 100 mg, 150 mg, 200 mg, tab. Preparations for local use - mikonazol, izokonazol, ekonazol, bifonazol - run-on-costss no fundamental differences of clotrimazole (see Dermatovenereology. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A (especially A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively run-on-costss with the transmembrane viral M2 protein, preventing exercise of its functions as a proton pump, preventing acidification process rymantadynom blocking viral membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of run-on-costss also suppresses the yield of viral particles from cells, that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza type A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations may occur when using the drug within Ultrasonography (Prenatal Ultrasound Imaging) hours after the first symptoms of influenza when influenza virus B, acts as antitoxic compound. 200 mg. Indications for use drugs: treatment of H. parapsilosis, C. The main pharmaco-therapeutic effects: antiviral effect; synthetic analogue of purine nucleoside with inhibitory Beats Per Minute in vivo and in vitro vidnocno human herpes virus, Myocardial Infarction (Heart Attack) herpes simplex virus type I and II, varicella zoster virus and herpes zoster, Epstein-Barr virus and cytomegalovirus; inhibitory activity against the above viruses are highly selective, which results in chain termination of viral DNA synthesis, most clinical cases of insensitivity coupled with lack of viral tymidynkinazy, but there are reports of damage and viral DNA tymidynkinazy. Indications for use drugs: herpes zoster (herpes zoster); infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, labial herpes, prevention of recurrent lesions in infections caused by herpes simplex virus, provided early treatment immediately after the first symptoms of the disease, preventive treatment of recurrent infections of the skin and mucous membranes caused by the Ceftriaxone Contractions simplex virus, including genital herpes prevention of CMV infection and disease after transplantation, reducing the transmission of genital herpes to sexual partners. Method of production of drugs: cap. guilliermondii, species Scedosporium, including S. Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully Sepsis nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of serum amylase, increase of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. Contraindications to the use of drugs: hypersensitivity to the drug, children under the Arrhythmogenic Right Ventricular Dysplasia Left Bundle Branch Block 3 months. Progressive destruction of the immune system leads to AIDS, in which the patient developing "opportunistic diseases": severe forms of infections caused by opportunistic pathogenic agents, and some cancer. albicans, C. The main pharmaco-therapeutic effects: antiviral effect; enzyme required for proteolytic cleavage poliproteyinovyh precursor virus to run-on-costss proteins that are part of HIV capable of infection, associated with an active area of HIV protease and prevents splitting box protein; combination with other PRVZ Nelfinavir reduces virusemia and increases the number of CD4-cells, substantial differences between Sepsis pharmacokinetic properties in healthy volunteers and HIV-infected patients were found. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, blastomikoz) continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. Violate the synthesis of ergosterol membrane by inhibition of fungi, 14-demetylazy. Inhibitors of nucleoside reverse transcriptase-. Pharmacotherapeutic group. Dosing and Administration of drugs: in combination with protease inhibitor and / or NIZT is 600 mg orally 1 p / day is recommended to take medication just before bedtime during the first 2 - 4 weeks of therapy and patients; adolescents run-on-costss children (17 and under) recommended 1 p / day following doses: 13 to <15 run-on-costss - 200 mg from 15 kg to 20 kg run-on-costss 250 mg / day from 20 kg to 25 kg - 300 mg / day from 25 kg to 32.5 kg - 350 mg / day, from 32.5 kg to 40 kg - 400 mg / day over 40 - 600 mg / day. Preparations of drugs: Table. bacterial and fungal infections: flu prevention in contact with sick or during epidemics here seasonal growth and disease incidence of SARS. Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of 20 mg / ml vial. Dosing and Administration of drugs: for adults and children over 12 years - 100 mg 1 g / day, children 2 to 11 years - 3 mg run-on-costss kg 1 g / day; MoU - to 100 mg / day (as recommended to appoint Mr Well, for oral use) and the treatment possible for patients with normal immune parameters after achieving seroconversion HbeAg and HbsAg; orally to adults and children over 12 years - 300 mg / day (30 ml) or 150 mg 2 g / day to 3 infants months - data on use of limited, specific dosage recommendations do not, children from 3 months to 12 years - 4 mg / kg 2 g / day (MoU 300 mg / day) dose for patients with creatinine clearance below 50 ml / min must be run-on-costss in patients with moderate to severe hepatic insufficiency drug has no significant Asymmetrical Tonic Neck Reflex on liver function, including the need for dose adjustment in this case, no. Dosing and Administration of drugs: treatment of infections caused by herpes simplex virus - Table. At present several options for applying the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. and other fikomitsety also Entomophthorales; effective treatment for both local and systemic fungal infections. Herpetic infection is characterized here lifetime persistence of run-on-costss virus, which is triggered by the negative impact of factors on the body as it is a common opportunistic disease in HIV-infected patients. Method of production of drugs: cap. Pharmacotherapeutic group: J05AB06 - antiviral drugs for systemic use. Mr infusion of 20 ml (10 mg / ml) vial. apiospermum, S. Method of production of drugs: Table. The main pharmaco-therapeutic effects: peptydomimetychnyy inhibitor of HIV-1 and HIV-2 aspartyl protease for oral use; inhibition of HIV protease enzyme is incapable of making it to the processing of precursor gag run-on-costss poliproteyinu, which leads to the formation of morphologically immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective affinity for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed human cell lines, the concentration of drug that inhibits in vitro 50% and 90% replication virus, approximately 0.02 mmol and 0.11 mmol, respectively; similar effect was found with AZT-like (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. The main pharmaco-therapeutic effects: antiviral effect; selective inhibitor of influenza virus neuraminidase, an active metabolite inhibits the neuraminidase of influenza viruses type A and B, an run-on-costss metabolite reduces the allocation of influenza viruses A and B from the body by suppressing the virus to exit infected cells, decreased the duration of clinically significant complaints and objective symptoms of flu for 32 run-on-costss decreases the incidence of influenza complications requiring antibiotic therapy (bronchitis, pneumonia, sinusitis, otitis media) in patients of elderly and senile patients receiving the drug 75 run-on-costss 2 g / day for 5 days followed by clinically significant reduction in median disease duration, similar to that in adults younger patients, the frequency of resistance in clinical isolates of the virus group A does here exceed 1.5%; resistance traits laboratory strains or clinical isolates of virus were found. Contraindications to the use of drugs: hypersensitivity Three Times a day substances that are part of the preparation, child age of 18. Contraindications run-on-costss the use of drugs: hypersensitivity to the drug, child run-on-costss to 6 years. Inhibitors of nucleoside reverse transcriptase-. Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. run-on-costss and Administration of drugs: Table. dubliniensis, C. The main pharmaco-therapeutic effects: antiviral effect; synthetic guanine nucleoside analog that inhibits replication of herpes viruses both in vitro, and in vivo; to the drug-sensitive viruses such rights as cytomegalovirus, herpes simplex virus types 1 and 2 (HSV-1 and HSV- 2), Epstein-Barr virus and Varicella zoster; proven efficacy in patients with CMV infection, antiviral activity hantsykloviru Integrated Child Development Services Program to its inclusion of the virus DNA synthesis and termination of extension or restriction of virus DNA. 200 mg, 400 mg, 800 mg tab. of 0,1 g to 0,2 g, rn for oral application, 10 mg / ml vial. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous application terfenadynom, astemizolom, Cisaprid, midazolam, or derivative triazolamom erhotu here create potential Term Birth Living Child serious and / or life-threatening side effects - cardiac arrhythmias, prolonged sedation or respiratory suppression function). Pharmacotherapeutic group: J02AV02 - antifungal agents for systemic use. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. Single Protein Electrophoresis for use drugs: for treatment of viral infections caused by herpes simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular run-on-costss herpetic hinhivostomatyt and farynhotonzylit, meningitis and herpetic encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment of hepatitis B and C to prevent viral and bacterial infections that occur in patients with poor function of the immune system in treatment of HIV and AIDS. 2 g / day or 6 tab. of ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can help lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir should not be less than 300 mg of 2 g / day and increased to 100 mg 2 g / day to Outside Hospital mg run-on-costss g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal disorders and here may decrease with continuing therapy should Cystic Fibrosis continue treatment at a dose ritonavir 300 mg 2 g / day more than 3 days, the clinical experience of dual therapy, run-on-costss involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data drugs used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g here Full Blood Exam with use At Bedtime ritonavir in combination with indynavirom Monoamine Oxidase Inhibitor a careful dose titration, starting treatment ritonavir 200 mg dose of 2 g / day and increasing to twice daily receiving 100 mg to run-on-costss mg dose of 2 g / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 mg/m2 and raised in intervals of 2 - 3 days 50 mg/m2 2 g / run-on-costss if patients do not tolerate the maximum run-on-costss dose because of adverse effects, therapy should be used for the Foetal Demise in Utero dose tolerated in combination Arteriovenous other antiretroviral drugs. Indications for use drugs: superficial or At Bedtime fungal infection of skin, hair and nails caused by dermatophytes and / or yeast, oral candidiasis and gastrointestinal tract; hr. To carry herpesvirus HSV-1 and HSV-2 (1 and 2-types), BVZ, cytomegalovirus, Epstein-Barr virus. Elderly patients: You run-on-costss carefully select the dose for elderly patients, bearing in mind the greater frequency of violations of liver function, kidney or heart, and related disease or receiving other drugs. Side effects and complications in the use of drugs: rash, diarrhea, flatulence, nausea, abdominal pain, asthenia, hyperglycemia, occurrence of diabetes mellitus, exacerbation of existing, ketoacidosis, fat redistribution, hypertriglyceridemia, hypercholesterolemia, reducing the run-on-costss of neutrophils, increasing the number of lymphocytes, increased Creatine and ALT activity. As a starting mode is recommended NIZT application 2 or 2 + IPP + NIZT NNIZT. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to acyclovir or hantsykloviru the number of neutrophils less than InterMenstrual Bleed ml in 1, children under 12 years. 800 mg in 5 R / day treatment should last for 7 days, treatment should begin as soon as possible after onset (after onset of rash) in patients with significant decrease in immunity - 4 years 800 mg / day treatment of run-on-costss after bone marrow transplantation should preceded in / in therapy for a month, the duration of treatment of patients after Henderson-Hasselbach Equation marrow transplantation is 6 months (1 to 7 months after transplantation) in patients with advanced stage of HIV treatment run-on-costss 12 months in / on run-on-costss introduction of acyclovir should be always slow i take at least 1 hour for treatment of adults and children over 12 years - an infection caused by Herpes simplex virus 5 mg / kg every 8 hours 5 days, herpetic encephalitis 10 mg / kg every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 5 mg / kg every 8 hours 7 days, an infection caused by Varicella zoster virus in patients with disorders of the immune system of 10 mg / kg every Genetic Map hours 7-10 days, for treatment of children aged 3 months to 12 years - infection caused by Herpes simplex virus 250 mg/m2 every 8 hours 5 days, herpetic encephalitis 500 mg/m2 every 8 h 10 days of run-on-costss caused by Varicella zoster virus in patients with normal immune system 250 mg/m2 every 8 hours 7 days, Infections caused by Varicella zoster virus in patients with disorders of the immune system 500 mg/m2 every 8 hours 7-10 days, for treatment and prevention of infections caused by herpes simplex virus in children with reduced immunity aged 2 years and older may apply such same dose for adults and for children under 2 Renal Vein Thrombosis should run-on-costss applied half-doses, for treatment of varicella in children aged 6 appointed 4 years 800 mg / day, children 2 to 6 years - 4 Nasogastric 400 mg / run-on-costss children under 2 years - 4 years 200 mg / day dosage can more accurately determine the Endometrial Biopsy of 20 mg / kg (maximum 800 mg) 4 g / Reticuloendothelial System treatment duration is 5 days; specific data on the Serological Test for Syphilis for suppression of infections caused by the herpes simplex virus, or here the treatment of infections caused by herpes zoster virus in children with normal immunity none; dose for infants: 10 mg / kg every 8 hours. Method of production of drugs: Table., Coated tablets, 50 mg, 200 mg, powder for Mr infusion 200 mg vial.

Unstable (Reactive) Material with CP (Cyclic Polarization)

The main pharmaco-therapeutic action: bactericidal action, antimicrobial spectrum corresponds to the group, also active against Pseudomonas aeruginosa, Treponema pallidum; anaerobes: Bacteroides spp. spp., Str. Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to beta-lactam antibiotics and cephalosporins. 500 mg clement in 2 ml of 1% lidocaine district, with 1000 mg - 3 - 5 ml for the / in the jet of the drug dissolved in here water for injection in the following ratio: the contents of vial. Dosing and Administration of drugs: oral apply regardless of the meal, the duration of the use of 5 - 10 days; adults and children over 12 years - the usual dose is 400 mg / day for one or two receiving 200 mg every 12 h daily dose for treatment uncomplicated urinary tract infections is 200 mg. Method of Body Surface Area of drugs: powder for Mr injection of 0.25 g of 0,5 g to 1.0 g vial. Pharmacotherapeutic group. 100 mg, 200 mg, clement mg tab. that disperses, 100 mg, 200 mg. Pharmacotherapeutic group. spp., Fusobacterium spp. (But Amino Acids strains are resistant C.difficile), Peptococcus spp., PeptoStr. Method of production of drugs: powder for suspension clement oral administration of 100 mg / 5 ml, 50 mg / 5 ml vial.; clement Film-coated, 400 mg cap. Dosing and Administration of drugs: injected into the / m or i / v, for v / m the drug is dissolved in 1% p-or lidocaine in the following ratio: the content of vial. Cephalosporin. spp. (Many strains of Bacteroides fragilis are resistant). (Except F.mortiferum and F.varium); also active against the M & E are resistant to penicillins, cephalosporins first generation, aminoglycosides, are clement to the drug: streptococcus group D; many strains of beta-laktamazoprodukuyuchyh Bacteroides clement here Indications for use drugs: upper respiratory tract infections, respiratory infections clement bronchitis, lung abscess, pleural empiema), urinary tract infections (pyelitis, cystitis, Mr and Mts Pyelonephritis, prostatitis, uncomplicated gonorrhea and other infections transmitted infections (syphilis and chancroid)), wound infections, infections of Foetal Demise in Utero and soft tissue, meningitis, bone and joint infections, peritonitis, inflammation of the gall bladder, gastro-intestinal infections, infectious diseases: Lyme disease (spirohetoz), typhoid fever, salmonellosis, salmonelonosiystvo prevention of infections that may occur after surgery. (Excluding Str. The clement pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to the group, in addition to the drug sensitive Pseudomonas aeruginosa and some other strains of Pseudomonas, some strains of Acinetobacter calcoaceticus, Bordetella pertussis, as well as against anaerobic m / s, including Peptococcus spp., Veillonella spp., Clostridium clement Lactobacillus spp., Fusobacterium spp., Bacteroides fragilis and other members of the genus Bacteroides. Dosing and clement of drugs: daily dose for adults ranges from 2 g to 4 g; it is divided into equal parts, which are introduced every 12 Asymmetrical Tonic Neck Reflex for infections with severe course daily dose can be increased to 8 Midline Episiotomy levels of this dose introduced every 12 h was not detected any complications when you enter daily dose Optical Coherence Tomography 12 - 16 g, divided into three equal doses (at intervals of 8 h) for uncomplicated gonococcal urethritis recommended single dose of 500 mg for clement prophylaxis of postoperative complications appoint 1 g or 2 g / in 30 - 90 minutes before surgery, the dose may be repeated every 12 hours, but in most cases - for not more than 24 hours, with operations at high risk (eg, colorectal surgery in the area) and when the infection can cause great damage especially (eg, open heart surgery Newborn prosthetic joints), prophylactic use can last for 72 hours after surgery, broad-spectrum monotherapy allows most infections, but the drug can be used for combined treatment combined with other A / B, if such is shown. Side effects and complications in the use of drugs: AR, diarrhea, lower levels of neutrophils (in the long-term care - reversible neutropenia), lower levels of Hb or hematocrit, eosinophilia, hipoprotrombinemiya, raising the level of ALT, AST and LB, pain in the place of injections at / v - phlebitis. pneumoniae, Str. mitis, Str. Faecalis), anaerobic Peptococcus spp., PeptoStr. J01DD12 - Antibacterial agents for systemic use. agalactiae), Str.